Title : Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model-Informed Dose Selection for Pediatric Development.

Pub. Date : 2022 Apr

PMID : 34699069






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The BCR-ABL1 inhibitor ponatinib is approved for the treatment of adults with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia, including those with the T315I mutation. ponatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens